A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

PHASE4TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 29, 2017

Study Completion Date

March 15, 2018

Conditions
End Stage Renal DiseaseHyperphosphatemiaChronic Inflammation
Interventions
DRUG

Ferric Citrate

Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and \< 50% and ferritin ≥ 200 and \< 500 ng/ml after a 2 week wash out period.

Trial Locations (1)

11501

Winthrop University Hospital, Mineola

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Keryx Biopharmaceuticals

INDUSTRY

lead

Winthrop University Hospital

OTHER